Solithromycin is a next-generation oral and intravenous fluoroketolide entering Phase II clinical development for the treatment of community-acquired bacterial pneumonia (CABP).
Macrolides & Infectious Disease
Macrolides are antimicrobial drugs that are active against aerobic and anaerobic gram-positive cocci and are prescribed for the treatment of respiratory tract and soft tissue infections.
Macrolides belong to the polyketide class of natural products. The macrolide ring - a large lactone ring to which one or more deoxy sugars, usually cladinose and desosamine, are attached - is responsible for the antimicrobial properties of this class. By reversibly binding to the 50S subunit of the bacterial ribosome, these drugs block protein synthesis, preventing bacterial growth and reproduction. This action is primarily bacteriostatic, however at higher concentrations, macrolides can be bactericidal. Some of the most commonly prescribed macrolides include erythromycin, azithromycin (Zithromax®) and clarithromycin (Biaxin®).
Ketolides belong to the macrolide class that is used to treat respiratory tract infections. These drugs are effective against macrolide-resistant bacteria because of their ability to bind to two sites on the bacterial ribosome. Examples include telithromycin (Ketek®) and cethromycin.
The spectrum of activity of macrolides includes streptococci as well as atypical bacteria such as Mycoplasma and Legionella and intracellular bacteria such as Chlamydia.
Acquired bacterial resistance to macrolides occurs primarily through post-transcriptional methylation of the 23S bacterial ribosome. This results in cross-resistance to macrolides, lincosamides and streptogramins. Although rare, acquired resistance can also result from the production of drug-inactivating enzymes such as esterases or kinases, as well as the production of active ATP-dependent efflux proteins that transport macrolides out of the cell. As more than 45% of pneumococci are resistant to currently available antibiotics, a new macrolide is greatly needed. To address this need Cempra Pharmaceuticals is developing Solithromycin.
Profile of Solithromycin
Solithromycin meets the requirements for a highly potent next-generation macrolide that retains activity against drug-resistant strains. In vitro and in vivo studies have shown potent activity against S. pneumoniae as well as an extended spectrum of activity against CA-MRSA, enterococci, M. avium and in animal models of malaria. It is also active against atypical bacteria, such as Legionella, Mycoplasma and Ureaplasma and against gonococci and other organisms that cause genitourinary tract infections. It is 8-16 times more potent than azithromycin and is active against azithromycin-resistant strains. Its activity against resistant strains is driven by its ability to bind to three sites on the bacterial ribosome, compared to two for current macrolides. The binding to three ribosomal sites is expected to limit resistance development.
Solithromycin does not contain a pyridine in the side chain of the molecule that could be associated with visual disturbances and exacerbations of myasthenia gravis that have been observed with telithromycin (Ketek?).
Phase I dose-escalation studies in healthy subjects showed that Solithromycin was safe and well tolerated. PK/PD results suggest that Solithromycin could be a once-daily oral treatment.
Research on Solithromycin
Publications
The links for the articles go to subscription-based sites and may require a fee to view the article.
In Vitro and In Vivo Activity of Solithromycin (CEM-101) against Plasmodium Species.
Wittlin, S., Ekland, E., Craft, J.C., Lotharius, J., Bathurst, I., Fidock, D.A., Fernandes, P.
Antimicrobial Agents and Chemotherapy. February 2012 56(2):703-7
http://www.ncbi.nlm.nih.gov/pubmed?term=fernandes%20malaria%20cem-101
Solithromycin
Fernandes, P., Pereira, D., Jamieson, B., and Keedy, K.
Drugs of the Future. October 2011 36(10): 751
http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1622079&p_IsPs=N
Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects.
J .G. Still, J. Schranz, T. P. Degenhardt, D. Scott, P. Fernandes, M. J. Gutierrez, and K. Clark
Antimicrobial Agents and Chemotherapy. May 2011 55:1997-2003
http://aac.asm.org/cgi/content/abstract/55/5/1997
Synthesis and antibacterial activity of novel 4-aryl-[1,2,3]-triazole containing macrolides
D. Pereira and P. Fernandes
Bioorganic and Medicinal Chemistry Letters January 2011 21: 510-513
http://www.ncbi.nlm.nih.gov/pubmed/21084187
Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci
S.D. Putnam, H.S. Sader, D.J. Farrell, D.J. Biedenbach, and M. Castanheira
International Journal of Antimicrobial Agents January 2011 37: 39-45
http://www.ncbi.nlm.nih.gov/pubmed/21084187
The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009)
D. J. Farrell, M. Castanheira, H. S. Sader, and R. N. Jones. 2010.
The Journal of Infection. December 2010 61: 476-483
http://www.ncbi.nlm.nih.gov/pubmed/20831882
Molecular Characterization of Off-Target Activities of Telithromycin: a Potential Role for Nicotinic Acetylcholine Receptors
D Bertrand, S Bertrand, E Neveu, and P Fernandes
Antimicrobial Agents and Chemotherapy. December 2010 54: 5399-5402
http://aac.asm.org/cgi/content/full/54/12/5399
Binding and Action of CEM-101, a New Fluoroketolide Antibiotic That Inhibits Protein Synthesis
B Llano-Sotelo, J Dunkle, D Klepacki, W Zhang, P Fernandes, J Cate, A Mankin
Antimicrobial Agents and Chemotherapy. December 2010 54: 4961-4970
http://aac.asm.org/cgi/content/full/54/12/4961
Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitides from a worldwide collection
D.J. Biedenbach, M. Castanheira, and R.N. Jones
Antimicrobial Agents and Chemotherapy. September 2010 54: 4009-4011
http://www.ncbi.nlm.nih.gov/pubmed/20625152
Antimicrobial characterization of CEM-101 activity against respiratory tract pathogens including multidrug-resistant pneumococcal serogroup 19A isolates
D.J. Farrell, H.S. Sader, M. Castanheira, D.J. Biedenbach, P.R. Rhomberg, and R.N. Jones
International Journal of Antimicrobial Agents. June 2010 35: 537-543
http://tinyurl.com/4jwmcdq
CEM-101 activity against Gram-positive organisms
L.N. Woosley, M. Castanheira, and R.N. Jones
Antimicrobial Agents and Chemotherapy. May 2010 54: 2182-2187
http://www.ncbi.nlm.nih.gov/pubmed/20176910
MIC quality control guidelines and disk diffusion test optimization for CEM-101, a novel fluoroketolide
R.N. Jones, J.E. Ross, P.R. Rhomberg, and Quality Control Working Group
Journal of Clininical Microbiology. April 2010 48: 1470-1473
http://jcm.asm.org/cgi/content/short/48/4/1470
CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-postive and Gram-negative bacteria
S.D. Putnam, M. Castanheira, G.J. Moet, D.J. Farrell, and R.N. Jones
Diagnostic Microbiology and Infectious Disease. April 2010 66: 393-401
http://www.ncbi.nlm.nih.gov/pubmed/20022192
In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae
P.M. Roblin, S.A. Kohlhoff, C. Parker, and M.R. Hammerschlag
Antimicrobial Agents and Chemotherapy. March 2010 54: 1358-1359
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825974/
In Vitro Activity of Solithromycin against Streptococcus pneumoniae and Streptococcus pyogenes with Defined Macrolide Resistance Mechanisms
P McGhee, C Clark, KM Kosowska-Shick, K Nagai, B Dewasse, L Beachel, PC Appelbaum
Antimicrobial Agents and Chemotherapy. January 2010 54: 230-238
http://aac.asm.org/cgi/content/abstract/54/1/230
Cellular Accumulation and Pharmacodynamic Evaluation of the Intracellular Activity of Solithromycin, a Novel Fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in Human THP-1 Macrophages
S Lemaire, F Van Bambeke, PM Tulkens
Antimicrobial Agents and Chemotherapy. September 2009 53: 3734-3743
http://aac.asm.org/cgi/content/abstract/53/9/3734
Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101
K.B. Waites, D.M. Crabb, and L.B. Duffy
Antimicrobial Agents and Chemotherapy. May 2009 53: 2139-2141
http://www.ncbi.nlm.nih.gov/pubmed/19258276
Anti-inflammatory Effects of Macrolides in a Model Relevant to CF Airway Epithelial Inflammation
Carla M. P. Ribeiro, Mary E.B. Martino, Brian Brighton and Prabha Fernandes
Download Abstract 
| Download Poster
Mechanistic Characterization of Adverse Events of Voriconazole and Telithromycin
Daniel Bertrand, Sonia Bertrand, David Pereira and Prabhavathi Fernandes
Download Abstract | Download Poster
Establishment of Quality Control Ranges for Testing the Susceptibility of Target Organisms to Solithromycin (CEM-101) by Disk Diffusion
J. Deane, C.M. Pillar, D.F. Sahm, S. Rowshan and P. Fernandes
Download Abstract | Download Poster
Side Effects of Telithromycin and Voriconazole are Attributable to Nicotinic Acetylcholine Receptor Interactions
D. Bertrand, S. Bertrand, D. Pereira and P. Fernandes
Download Abstract | Download Poster
Intravenous Formulation of Solithromycin, a Painless Macrolide Antibiotic in a Rabbit Intravenous Injection Model
P. Fernandes, D. Pereira, S. Wu and A. Slee
Download Abstract | Download Poster
Activity of 9 Antibiotics Against Intracellular Forms of S. pneumonia
S Lemaire, F Van Bambeke, P Tulkens
Download Abstract | Download Poster
Ribosomal Mutations Associated with Ketolide Resistance in Haemophilus Influenzae Found in the SENTRY Antimicrobial Surveillance Program
DJ Farrell, LM Deshpande, RE Mendes, RN Jones
Download Abstract | Download Poster
Antimicrobial Activity of Solithromycin (CEM-101), a Novel Fluoroketolide, Tested Against Isolates Collected in Europe during 2010 Surveillance
DJ Biedenbach, HS Sader, RN Jones, DJ Farrell
Download Abstract | Download Poster
A Phase 1 Trial to Evaluate the Safety and Pharmacokinetics of Single Doses of Intravenous (IV) Solithromycin(CEM-101) in Healthy Adult Subjects
J Schranz, K Clark, A Marion, G Ghibellini, P Fernandes
Download Abstract
Mycobacterium leprae is Susceptible to Solithromycin (CEM-101)
R. Lahiri, T.P. Gillis, J.L. Krahenbull, P. Fernandes
Download Abstract | Download Poster
Solithromycin (CEM-101) - A New Fluoroketolide with Antimalarial Activity
J.C. Craft, S. Wittlin, J. Lotharius, I. Bathurst, P. Fernandes
Download Abstract | Download Poster
Anti-malarial Activity of CEM-101, A Fluoroketolide Antimicrobial, in Both Bloodstage and Presumptive Causal
S. Fracisco, M. Gettayacamin, A. Tungtaeng, M. Kozar, M. O'Neil, C. Craft, P. Fernandes
Download Abstract | Download Poster
Molecular Characterization of Off-Target Activities of Telithromycin, a Macrolide/Ketolide Antibiotic:The Role of Nicotinic Acetylcholine Receptors
D. Betrand, S. Bertrand, E. Neveu and P. Fernandes
Download Abstract | Download Poster
Antimicrobial Activity of a New Fluoroketolide Solithromycin (formerly CEM-101) Tested Against Fastidious Gram-negative Community-Acquired Bacterial Pneumonia Pathogens
D.J. Biedenbach, D.J. Farrell, H.S. Sader, R.N. Jones
Download Abstract | Download Poster
Antimicrobial Activity of a New Fluoroketolide(CEM-101) Tested Against Streptococcus pneumoniae
Tested by the SENTRY Surveillance Program (2008-2009)
D.J. Biedenbach, R.N. Jones , D.J. Farrell, H.S. Sader
Download Abstract | Download Poster
Mutations Associated with KetolideResistance in Streptococcus pneumonia Collected in the 2009 SENTRY Antimicrobial Surveillance Program
D.J. Farrell, L.M. Deshpande, R.E. Mended, R.N. Jones
Download Abstract | Download Poster
In vitro and In vivo activity of Solithromycin, a new fluoroketolide, against Mycobacterium avium complex
C.M. Shoen, M.S. DeStefano, M.R. Sklaney, M.H. Cynamon
Download Abstract | Download Poster
Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis of Solithromycin Against Streptococcus pneumoniae Using Data from a Murine-Lung Infection Model
D. R. Andes, O. O. Okusanya, A. Forrest, S. M. Bhavnani, P. Fernandes, P. G. Ambrose
Download Abstract | Download Poster
Evaluation of Solithromycin (CEM-101), a Novel Fluroketolide, in Murine Infection Models
T. M. Murphy, S. Little, A. M. Slee , P. Fernandes
Download Abstract | Download Poster
Development of an Intravenous Formulation of Solithromycin (CEM-101), a Novel, Potent Fluoroketolide
P Fernandes, T Degenhardt, D Pereira
Download Abstract | Download Poster
Comparison of Solithromycin Metabolism in Mice, Rats, Monkeys and Human
D. Pereira, T Degenhardt, P Fernandes
Download Abstract | Download Poster
Intrapulmonary Penetration of Solithromycin in Healthy Adult Subjects
K. A. Rodvold, M. H. Gotfried, O. O. Okusanya, A. Forrest, S. M. Bhavnani, J. G. Still, K. Clark, P. Fernandes, P. G. Ambrose
Download Abstract | Download Poster
Population Pharmacokinetics (PPK) of Solithromycin Using Data from the Plasma and Epithelial Lining Fluid (ELF) of Healthy Subjects
O. O. Okusanya, A. Forrest, S. M. Bhavnani, K. A. Rodvold, M. H. Gotfried, P. Fernandes, K. Clark, J. G. Still, P. G. Ambrose
Download Abstract | Download Poster
Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment (TA) Analysis Supporting Solithromycin Phase 2 Dose Selection
O. O. Okusanya, S. M. Bhavnani, A. Forrest, P. Fernadnes, P. G. Ambrose
Download Abstract | Download Poster
Phase 1 Pharmacokinetic and Safety of Multiple Doses and Effects of Food on the Bioavailability of Oral Solithromycin (CEM-101) in Healthy Adult Subjects
J. Schranz, K. Clark, T. Degenhardt, D. Scott, P. Fernandes, J. G. Still, J., Kissling, S. Sharples
Download Abstract | Download Poster
Solithromycin (CEM-101), a Novel Fluoroketolide with Exceptional Cellular Accumulation, Localizes in Lysosomes and Induces Phospholipidosis but no Apoptosis and does not Interfere with the Production of Reactive Oxygen Species(ROS) in Cultured. Comparison with Azithromycin (AZM) and Gentamicin (GEN)
D. Das, F. Van Bambeke, P.M. Tulkens
Download Abstract | Download Poster
In vitro activity of CEM-101 compared to clarithromycin against Nocardia species
C. Flores-Penalba, C. Shoen, M. DeStefano, and M. Cynamon
Download Abstract | Download Poster
Superior anti-inflammatory effects of a novel macrolides/fluoroketolide, CEM-101 in monocytic cells
Y. Kobayahsi, C. Rossios, P.J. Barnes, and K. Ito
Download Abstract | Download Poster
A novel macrolides/fluoroketolide, CEM-101 reverses corticosteroid sensitivity under oxidative stress via P13K pathway inhibition
Y. Kobayashi, C. Rossios, D. Takagi, P.J. Barnes, and K. Ito
Download Abstract | Download Poster
Multiple Dose Pharmacokinetics and Safety of Solithromycin, a New Fluoroketolide, in Healthy Subjects
J.G. Still, K. Clark, T. Degenhardt, D. Scott, P. Fernandes
Download Abstract | Download Poster
Solithromycin, a novel fluoroketolide, tested against European clinical isolates from 2009 (first-year surveillance results)
R. Jones, D. Farrell, H. Sader, M. Stilwell, M. Castaheira
Download Abstract | Download Poster
Solithromycin, a novel ketolide; in vitro activity against Legionella pneumophila
J. Dubois, P. Fernandes
Download Abstract | Download Poster
Solithromycin, a novel ketolide, in vitro activity against resistant strains of Streptococcus pnuemoniae and Haemophilus influenza
J. Dubois, P. Fernandes
Download Abstract | Download Poster
Expanded studies of Solithromycin, a novel fluoroketolide, tested against invasive isolates of N. meningitidis, including flouroquinolone-non-susceptible resistant strains
R. Jones, D. Biedenbach, L. Woosley, G.Gerken, M. Castaheira
Download Abstract | Download Poster
Solithromycin, a novel fluoroketolide: Activity against recent(2008) isolates of multidrug-resistant (MDR) S. pneumoniae (SPN)
R.N. Jones , M.G. Stilwell H.S. Sader, P. Fernandes
Download Abstract | Download Poster
Activity of Solithromycin, a Novel Fluoriketolide, Tested Against Invasive Isolates of N. meningitides (NM) from a Worldwide Collection
DJ Biedenbach, LN Woosley, GD Gerken, HS Sader, RN Jones
Download Abstract | Download Poster
In Vitro Activity of Solithromycin against Legionella Spp.
J Dubois, P Fernandes
Download Abstract | Download Poster
In Vitro Activity of Solithromycin Against Resistant Strains of Staphylococcus aureus
J Dubois, P Fernandes
Download Abstract | Download Poster
Capability of Solithromycin to Select for Resistant Pneumococcal and Group A Streptococcal Clones by Multistep Resistance Selection
C Clark, K Kosowska-Shick, P McGhee, PC Appelbaum
Download Abstract | Download Poster
Proposed Mechanisms to Explain the Unusual Visual Disturbances Associated with Telithromycin
D Bertrand, S Bertrand, P Fernandes
Download Abstract | Download Poster
First Year Antimicrobial Surveillance Results for Solithromycin, a Novel Fluoroketolide with Potent Activity Against Pathogens Associated with Community-acquired Bacterial Pneumonia (CABP)
RN Jones, HS Sader, MJ Janechek, GJ Moet
Download Abstract | Download Poster
Evaluation of Solithromycin, a Novel Fluoroketolide, in a Rat H. influenzae Pulmonary Infection Model
T Murphy, S Little, R Wu, A Slee, P Fernandes
Download Abstract | Download Poster
Pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoro ketolide, towards Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages
S. Lemaire, F. Van Bambeke, and P.M. Tulkens
Download Abstract | Download Poster
Antimicrobial Characterization of Solithromycin: Activity Against Staphylococci, β-Haemolytic and Viridans Group Streptococci
R.N. Jones, H.S. Sader, D.J. Biedenbach
Download Abstract | Download Poster
Activity of Solithromycin Tested Against Emerging Telithromycin-Resistant β-Haemolytic Streptococci
R.N. Jones, L.N. Woosley, G.J. Moet, P.R. Rhomberg
Download Abstract | Download Poster
Comparative Activities of the Novel Ketolide Solithromycin and Telithromycin (TEL) Towards Streptococcus pneumoniae (SP) Resistant to Macrolides (ML) from Patients with Confirmed Community-Acquired Pneumonia (CAP)
A.Lismond, F. Bambeke, P.M. Tulkens
Download Abstract | Download Poster
Efficacy and Pharmacodynamic Evaluation of Solithromycin, a Novel Macrolide, in Murine Infection Models
T.M. Murphy, M. Gaffney, S. Little, R. Wu, A.M. Slee, C. Ong, P. Fernandes
Download Abstract | Download Poster
SAR of 11, 12-Carbamate Macrolides/Ketolides Linked With 1,4-Substituted-[1,2,3]-Triazoles
C Hwang, J Duffield, Y Chiu, C Liang, S Yao, N Roberts, F Babakhani, P Sears, Y Shue, Y Ichikawa, P Fernandes, D Pereira, A Romero
Download Abstract | Download Poster
Binding and Action of Solithromycin, a New Macrolide/Ketolide in Development for Treating Infections with Macrolide-Resistant and Macrolide-Susceptible Bacteria
B Llano-Sotelo, D Klepacki, N Vazquez-Laslop, AS Mankin
Download Abstract | Download Poster
Video: Alexander S. Mankin discusses binding of Solithromycin 
Activity of Solithromycin Compared to Other Agents Against Macrolide Susceptible and-Resistant Streptococci
P McGhee, K Nagai, PC Appelbaum
Download Abstract | Download Poster
Antimicrobial Characterization of Solithromycin: Activity Against 331 Respiratory Tract Pathogens Including Multidrug-Resistant Pneumococcal Serogroup 19A (MDR-19A) Isolates
RN Jones, DJ Biedenbach, PR Rhomberg, TR Fritsche, HS Sader
Download Abstract | Download Poster
Video: Ronald N. Jones discusses Solithromycin research
Antimicrobial Characterization of Solithromycin: Activity Against Enterococci, Uncommon Gram-positive Pathogens, N. gonorrhoeae and Anaerobes
DJ Biedenbach, LM Deshpande, TR Fritsche, HS Sader, RN Jones
Download Abstract | Download Poster
Video: Ronald N. Jones discusses Solithromycin research
Antimicrobial Characterization of Solithromycin: Potential Application Against Species Causing Enteritis/Gastroenteritis
RN Jones, HS Sader, TR Fritsche, DJ Biedenbach, M Castanheira
Download Abstract | Download Poster
Video: Ronald N. Jones discusses Solithromycin research
In Vitro Activity of Solithromycin, a New Ketolide Antibiotic, Against Chlamydia trachomatis and Chlamydia pneuomoniae
PM Roblin, SA Kohlhoff, MR Hammerschlag
Download Abstract | Download Poster
Antimicrobial Activity of Solithromycin a New Macrolide, Tested Against Diverse Collections of Bacterial Biowarfare/Bioterrorism (BW/BT) Agents
HS Heine, L Miller, J Bassett, K Holman
Download Abstract | Download Poster
Comparative In Vitro Susceptibilities of a New Investigational Macrolide Solithromycin Against Human Mycoplasmas and Urealplasmas
KB Waites, DM Crabb, LB Duffy
Download Abstract | Download Poster
Solithromycin, a Novel Macrolide/Ketolide, Shows Improved Intracellular Activity Against Phagocytised S. aureus in Comparison with Azithromycin (AZM), Clarithromycin (CLR), or Telithromycin (TEL)
S Lemaire, F Van Bambeke, PM Tulkens
Download Abstract | Download Poster
Video: Paul Tulkens discusses intracellular activity of Solithromycin
Antimicrobial Characterization of Solithromycin: PAE, Bactericidal Activity and Combinations
HS Sader, DJ Biedenbach, PR Rhomberg, RN Jones
Download Abstract | Download Poster
Video: Ronald N. Jones discusses Solithromycin research
Antimicrobial Characterization of Solithromycin: Single Step, Selection by Passaging and Inducible Resistances
RN Jones, PR Rhomberg, HS Sader
Download Abstract | Download Poster
Video: Ronald N. Jones discusses Solithromycin research
Influence of Inhibitors of P-glycoprotein (P-gp) and Multidrug Resistance-Associated Protein (MRP) on the Accumulation and Intracellular Activity of Solithromycin, a Novel Macrolide/Ketolide, in Human THP-1 Macrophages: Comparison with Azithromycin
S Lemaire, F Van Bambeke, PM Tulkens
Download Abstract | Download Poster
Video: Paul Tulkens discusses intracellular activity of Solithromycin
Proposed MIC Quality Control Ranges for Solithromycin Using the CLSI Multi-Laboratory M23-A2 Study Design
PR Rhomberg, JE Ross, RN Jones
Download Abstract | Download Poster
Video: Ronald N. Jones discusses Solithromycin research
Assessment of Solithromycin Susceptibility Testing Conditions and Optimization of Disk Diffusion Methods
RN Jones, TR Fritsche, HS Sader, DJ Biedenbach, PR Rhomberg
Download Abstract | Download Poster
Video: Ronald N. Jones discusses Solithromycin research
Evaluation of Solithromycin, a Novel Macrolide, in Murine Infection Models
TM Murphy, S Little, M Gaffney, AM Slee, P Fernandes
Download Abstract | Download Poster
Video: Andrew M. Slee discusses Solithromycin data
Single Oral Dose Pharmacokinetics and Safety of Solithromycin in Healthy Subjects
JG Still, K Clark, TP Degenhardt, D Scott, P Fernandes, MJ Gutierrez
Download Abstract | Download Poster